These findings extend to patients, where biologic therapies targeting IL-23 and IL-17A or their receptors have demonstrated clinical efficacy in psoriasis, psoriatic arthritis, autoimmune uveitis and ankylosing spondylitis. This evidence concerns the gene IL17A and ankylosing spondylitis.